Cost Considerations in the Medical Management of Glaucoma in the US: Estimated Yearly Costs and Cost Effectiveness of Bimatoprost Compared with Other Medications

Author： Soto Javier  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.24, Iss.5, 2006-01, pp. : 519-520

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost Considerations in the Medical Management of Glaucoma in the US: Estimated Yearly Costs and Cost Effectiveness of Bimatoprost Compared with Other Medications

By Goldberg Lawrence D.  

PharmacoEconomics, Vol. 24, Iss. 3, 2006-01 ,pp. : 251-264

Adis International

Access to resources Recommend Favorite

Estimating `Costs' for Cost-Effectiveness Analysis

By Miners Alec  

PharmacoEconomics, Vol. 26, Iss. 9, 2008-01 ,pp. : 745-751

Adis International

Access to resources Recommend Favorite

Estimated Comparative Costs of Achieving a 20% Reduction in Intraocular Pressure with Bimatoprost or Latanoprost in Patients with Glaucoma or Ocular Hypertension

By Fiscella Richard  

Drugs & Aging, Vol. 23, Iss. 1, 2006-01 ,pp. : 39-47

Adis International

Access to resources Recommend Favorite

An eye for cost-effective drugs cuts costs in glaucoma

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 415, 2003-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite

An eye for cost-effective drugs cuts costs in glaucoma

By  

Inpharma, Vol. 1, Iss. 1390, 2003-01 ,pp. : 5-6

Adis International

Access to resources Recommend Favorite